2. UroToday Home
  3. Trials in Progress

Trials in Progress

ARASTEP: A Study to Compare Darolutamide Given With ADT vs ADT Alone in Men With Nonmetastatic Prostate Cancer

Trials in Progress
Videos

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Cancer
  • Study ID: NCT05794906
View Trial
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Alicia Morgans, MD, MPH
The 2023 ESMO annual meeting included a trial in progress session on prostate cancer, featuring a presentation by Dr. Alicia Morgans discussing ARASTEP, a phase 3, randomized, double-blind, placebo-controlled study assessing darolutamide + ADT in patients with high-risk biochemical recurrence of prostate cancer.